for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vir Biotechnology Inc

VIR.OQ

Latest Trade

49.70USD

Change

0.00(-0.00%)

Volume

432,173

Today's Range

49.11

 - 

54.14

52 Week Range

25.31

 - 

141.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Vir Biotechnology Provides Corporate Update And Reports Q2 Results

Aug 5 (Reuters) - Vir Biotechnology Inc <VIR.O>::VIR BIOTECHNOLOGY PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS.Q2 REVENUE $177.1 MILLION.Q2 REVENUE ESTIMATE $84.6 MILLION -- REFINITIV IBES DATA.QTRLY EARNINGS PER SHARE DILUTED $0.46.AS OF JUNE 30, 2021, EXCLUDING RESTRICTED CASH, HAD ABOUT $876.7 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.

GSK And Vir Biotechnology Announce Joint Procurement Deal With European Commission For Sotrovimab

July 28 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GSK AND VIR BIOTECHNOLOGY ANNOUNCE JOINT PROCUREMENT AGREEMENT WITH EUROPEAN COMMISSION FOR COVID-19 TREATMENT, SOTROVIMAB.GSK - AGREEMENT WITH THE EUROPEAN COMMISSION TO SUPPLY UP TO 220,000 DOSES OF SOTROVIMAB.GSK - CONTINUING TO EVALUATE ABILITY OF SOTROVIMAB TO MAINTAIN ACTIVITY AGAINST NEW AND EMERGING VARIANTS THROUGH IN VITRO STUDIES.GSK - CONTINUING TO EVALUATE ABILITY OF SOTROVIMAB TO MAINTAIN ACTIVITY AGAINST NEW AND EMERGING VARIANTS THROUGH IN VITRO STUDIES.

Singapore Health Regulator Grants Interim Authorisation For Glaxosmithkline's Sotrovimab For Treatment Of Covid-19 Infection

June 30 (Reuters) - :SINGAPORE HEALTH REGULATOR GRANTS INTERIM AUTHORISATION FOR GLAXOSMITHKLINE'S SOTROVIMAB FOR TREATMENT OF COVID-19 INFECTION. (Reporting By Aradhana Aravindan). ((aradhana.aravindan@thomsonreuters.com;)).

GSK, Vir Biotechnology To Supply sotrovimab To Govt of Singapore

June 30 (Reuters) - GSK: :CO AND VIR BIOTECHNOLOGY ENTER AGREEMENT WITH GOVERNMENT OF SINGAPORE FOR SUPPLY OF SOTROVIMAB.SOTROVIMAB IS FOR TREATMENT OF PATIENTS WITH COVID-19 NOT REQUIRING OXYGEN SUPPLEMENTATION AND AT RISK OF SEVERE COVID-19.SOTROVIMAB CURRENTLY UNDERGOING REVIEW BY SINGAPORE HEALTH SCIENCES AUTHORITY FOR INTERIM AUTHORIZATION.CO AND VIR IN DISCUSSIONS WITH OTHER GOVTS TO EXPLORE SIMILAR SUPPLY DEALS.Further company coverage: GSK.L. ((Reuters.Briefs@thomsonreuters.com;)).

Vir Biotechnology Presents New Clinical Data From Ongoing Trials Of Vir-2218 And Vir-3434 In Patients With Chronic Hepatitis B Virus Infection At The International Liver Congress 2021

June 25 (Reuters) - Vir Biotechnology Inc <VIR.O>::VIR BIOTECHNOLOGY PRESENTS NEW CLINICAL DATA FROM ONGOING TRIALS OF VIR-2218 AND VIR-3434 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION AT THE INTERNATIONAL LIVER CONGRESS 2021.VIR BIOTECHNOLOGY INC - RESULTS DEMONSTRATE POSITIVE SAFETY FINDINGS PLUS A REDUCTION IN HEPATITIS B SURFACE ANTIGEN (HBSAG) FOR BOTH COMPOUNDS.

GSK & Vir Biotechnology Announce Sotrovimab Receives Emergency Use Authorization From The US FDA

May 26 (Reuters) - Gsk <GSK.L>::GSK & VIR BIOTECHNOLOGY ANNOUNCE SOTROVIMAB EUA FROM US FDA FOR TREATMENT OF MILD-TO-MODERATE COVID-19 IN HIGH-RISK ADULTS AND PAEDIATRIC PATIENTS.DISCUSSIONS WITH GLOBAL REGULATORS REGARDING AUTHORISATIONS IN ADDITIONAL COUNTRIES CONTINUE TO ADVANCE.SOTROVIMAB WILL BE AVAILABLE FOR APPROPRIATE PATIENTS DIAGNOSED WITH COVID-19 IN THE U.S. IN THE COMING WEEKS.GSK AND VIR PLAN TO SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) TO THE FDA IN THE SECOND HALF OF 2021.

FDA Says Authorizing Emergency Use Of Sotrovimab For Treatment Of Covid-19

May 26 (Reuters) - GlaxoSmithKline PLC <GSK.L>::FDA SAYS AUTHORIZING EMERGENCY USE OF SOTROVIMAB FOR TREATMENT OF COVID-19.FDA SAYS AUTHORIZING EMERGENCY USE OF SOTROVIMAB FOR TREATMENT OF COVID-19.FDA SAYS REASONABLE TO BELIEVE GSK-VIR ANTIBODY SOTROVIMAB MAY BE EFFECTIVE FOR TREATMENT OF MILD-TO-MODERATE COVID-19 IN ADULTS & PEDIATRIC PATIENTS.

EMA Recommends Conditional Use of Sotrovimab To Treat COVID-19 In Adults, Adolescents

May 21 (Reuters) - GlaxoSmithKline PLC <GSK.L>::EMA SAYS CONCLUDED SOTROVIMAB CAN BE USED TO TREAT COVID-19 IN ADULTS AND ADOLESCENTS NOT REQUIRING SUPPLEMENTAL OXYGEN THERAPY AND RISK OF PROGRESSING TO SEVERE COVID-19.EMA SAYS A ROLLING REVIEW OF SOTROVIMAB, WHICH STARTED ON 7 MAY, IS ONGOING.

EMA Starts Rolling Review Of Sotrovimab (VIR-7831) For Treatment Of COVID-19

May 7 (Reuters) - EMA::EMA SAYS EMA STARTS ROLLING REVIEW OF SOTROVIMAB (VIR-7831) FOR COVID-19.EMA SAYS CHMP HAS STARTED A ‘ROLLING REVIEW’ OF DATA ON SOTROVIMAB (ALSO KNOWN AS VIR-7831 AND GSK4182136).EMA SAYS STARTED EVALUATING THE FIRST BATCH OF DATA, WHICH COME FROM LABORATORY AND ANIMAL STUDIES, IN ADDITION TO DATA ON THE QUALITY OF THE MEDICINE.EMA SAYS HAS NOT YET RECEIVED FULL DATASET AND IT IS TOO EARLY TO DRAW ANY CONCLUSIONS REGARDING THE BENEFIT-RISK BALANCE OF THE MEDICINE.

Vir Biotechnology Provides Corporate Update And Reports First Quarter 2021 Financial Results

May 6 (Reuters) - Vir Biotechnology Inc <VIR.O>::VIR BIOTECHNOLOGY PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS.VIR BIOTECHNOLOGY INC - TOTAL REVENUES FOR QUARTER ENDED MARCH 31, 2021, WERE $2.0 MILLION, COMPARED TO $5.7 MILLION FOR SAME PERIOD IN 2020.VIR BIOTECHNOLOGY - AS OF MARCH 31, 2021, EXCLUDING RESTRICTED CASH, COMPANY HAD APPROXIMATELY $733.0 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.VIR BIOTECHNOLOGY INC - QTRLY LOSS PER SHARE $1.32.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up